Global Bovine Lactoferrin Market is segmented By Type (Spay dried powder, Freeze-dried powder), By Application (Infant formula, Dietary supplements, Pharmaceutical, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Bovine Lactoferrin Market Report Overview
The Global Bovine Lactoferrin Market report provides an analysis of the market size, current trends, competitive landscape, and future market outlook. The demand for bovine lactoferrin is increasing due to its wide range of applications in the food and beverage, and pharmaceutical industries. The market is witnessing a surge in demand from the Asia-Pacific region, where consumers are increasingly adopting health and wellness products. The competitive rivalry is intensifying with major players such as Fonterra Co-operative Group Limited, FrieslandCampina, Synlait Milk Limited and others actively operating in the market.
Lactoferrin protein can be found in both human and cow milk. Bovine lactoferrin (bLF) has been shown to have anti-infective, anti-cancer, and anti-inflammatory properties when consumed. Oral bLF, in particular, is effective against infections of both digestive and non-digestive tract tissue in a variety of animal models.
Bovine Lactoferrin Market Scope
|
Metrics |
Details |
|
Market CAGR |
High |
|
Segments Covered |
By Type, By Application, and By Region |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
|
Fastest Growing Region |
Asia Pacific |
|
Largest Market Share |
North America |
To Know More: Download Sample
Bovine Lactoferrin Market Dynamics
The development of the immune system and the benefits associated with bovine lactoferrin are estimated to drive the market.
The development of the immune system is estimated to drive the bovine lactoferrin market
Lactoferrin is regarded to be the most polyvalent protein in vertebrate tissue defence against infections and traumas. It possesses antibacterial capabilities and affects innate and adaptive immune responses due to the proclivity of its basic N-terminal domain to interact with multiple microbial and host targets. Lactoferrin can influence immune cell activation, migration, and proliferation in both positive and negative ways. While lactoferrin's immunomodulatory effects have been demonstrated in vivo utilizing lactoferrin deletion, lactoferrin-overexpressing transgenic animals, and dietary lactoferrin, few pathways have been postulated in vitro research.
While lactoferrin's immunomodulatory effects have been demonstrated in vivo utilizing lactoferrin deletion, lactoferrin-overexpressing transgenic mice, and dietary lactoferrin, few mechanisms have been proposed to explain these properties based on in vitro research. Recent studies in humans provided evidence that oral supplementation with lactoferrin contributed to immune stimulation. The lactoferrin-based product increases immunological activities via inducing TGF and Wnt signaling pathways, as well as many genes encoding molecular effectors involved in the innate immune response, according to the study. Lysozymes (which mediate antibacterial defence by cleaving bacterial cell walls), saposins (peptides with antibacterial activity that create ion channels in target cell membranes), and lectins are all members of this gene family (proteins involved in pathogen detection).
The benefits associated with the use of bovine lactoferrin are estimated to drive the market
Bovine lactoferrin (bLF) has been shown to have anti-infective, anti-cancer, and anti-inflammatory properties when consumed. Oral bLF, in particular, is effective against infections of both digestive and non-digestive tract tissue in a variety of animal models. Furthermore, clinical trials on individuals with Helicobacter pylori infection, chronic hepatitis, tinea pedis, and other disorders have shown that bLF has beneficial effects. Immunomodulation in the intestinal and systemic locations may mediate the protective effects of oral bLF against infection.
Recently it was established that oral bLF has antiviral properties in influenza virus-infected mice. The amount of infiltrating leukocytes in the bronchoalveolar lavage fluid was reduced after BLF treatment. Using the quantitative RT-PCR method, oral bLF on the transcription of genes associated with immunity in the small intestine of mice was studied. The expression of IL-12p40, IFN-beta, and NOD2 was observed to be elevated after consuming bLF. As a result, oral bLF promotes the transcription of key immune-related genes in the small intestine, potentially promoting systemic host immunity.
Side effects associated with lactoferrin are estimated to hamper the bovine lactoferrin market
Lactoferrin, in the amounts found in food, is likely safe. Consuming larger levels of lactoferrin from up to a year from cow's milk is possibly safe. For up to 14 days, human lactoferrin generated from specifically processed rice appears to be safe. Lactoferrin has the potential to cause diarrhea. Skin rash, loss of appetite, weariness, cold, and constipation have all been recorded in high doses.
High amounts of lactoferrin can cause diarrhea, chills, weariness, loss of appetite, and constipation, among other things. People are concerned about mad cow disease since lactoferrin can be obtained from cows. The proper daily dosage of derived from dietary supplements is between 10 and 1200mg. To be safe, seek advice from a healthcare practitioner about a dosage that is appropriate for a particular age, health state, and nutritional requirements.
COVID-19 Impact on Bovine Lactoferrin Market Growth
Lactoferrin (LF) is a harmless iron-binding glycoprotein found in the milk of most animals. It has antiviral activity across a wide range of viruses, including coronaviruses. LF also has anti-inflammatory, anti-infective, and immune-regulating capabilities in line with SARS-CoV-2 infection therapy requirements. As a result, LF may be useful in the prevention and treatment of COVID-19. Furthermore, compared with other antiviral drugs, LF has a better safety profile. The use of LF may therefore hold promising results in the treatment of COVID-19 and warrants further investigation. Hence, there is an estimated scope for it in the market.
Bovine Lactoferrin Market Segment and Shares
The spray-dried segment is estimated to dominate the market
Spray drying and freeze-drying were used to create bovine lactoferrin (LFb) powders. As a starting material, industrially obtained fresh liquid-LFb was used. Spray-dried (SDLFb) and powder were analyzed for antioxidant capacity, water-solubility, moisture sorption behavior, denaturation extent, and changes in secondary structural characteristics. The SDLFb and FDLFb were further tested for residual moisture content, water activity, particle size, and amorphous/crystalline nature. In comparison to liquid-LFb, both SDLFb and FDLFb powders demonstrated minor denaturation and conformation changes. With nearly similar monolayer moisture content, both SDLFb and FDLFb showed type II sorption behavior. The SDLFb powders were amorphous in form and had a water solubility of >98 percent. SDLFb's antioxidant activity was comparable to that of liquid-LFb; however, it was 6% lower in FDLFb. A spray drying technique with 180°C inlets and 95°C outlet temperature was found to generate equivalent or superior quality LFb powders than a freeze-drying process based on residual moisture content, water activity, solubility, and preservation of the secondary structure of LFb in resultant powders.
Most companies have opted for the spray-dried technique. For example, Plants and processes designed by GEA to help optimize powder yield, hygiene, and plant operability. Multiple steps in the process are covered by GEA expertise, including the use of CEE high-efficiency cyclones for dust separation. MILEI GmbH, the German subsidiary of the Japanese Morinaga Milk Industry Co., Ltd., has chosen GEA spray dryer solutions for their recently expanded manufacturing facility in Germany. This company is the largest producer of lactoferrin globally and one of the first companies in the world to produce lactoferrin commercially.
The infant formula segment is estimated to dominate the bovine lactoferrin market
Lactoferrin is found naturally in all mammals’ milk (it is the second most abundant protein in a mother's milk). Hence infant formulae enriched with bovine lactoferrin are well tolerated by babies. Lactoferrin supplementation in reconstituted infant formulae (ready-to-use) is permitted in Europe and China at a concentration of 1 g/L. This glycoprotein aids in the development of a newborn's immune system. Lactoferrin may potentially activate the well-known protective effects of breastfeeding, increasing pathogen resistance in newborns. That is why lactoferrin-fortified newborn formulae have been available for years, particularly in Asian nations, but also in the United States and Europe. For practical lactoferrin applications, infant nutrition is the primary market. However, other sectors make use of the functional and nutritional properties of this protein.
Danone, Nestlé (GERBER), Abbott (SIMILAC), and Mead Johnson (ENFAMIL) are among the companies working to create a formula that closely resembles real breast milk. Aside from lactose and fat, a mother's milk contains hundreds of other components that differ from one mother to the next and even from one feeding to the next. In the search for an alternative to breast milk, the infant formula segment is estimated to dominate the market.
Bovine Lactoferrin Market Geographical Analysis
North America region is estimated to dominate the bovine lactoferrin market
The FDA approval and presence of major key players in this region are estimated to dominate the market.
The US FDA recently cleared lactoferrin for use in infant formula. The demand value of U.S. lactoferrin was about 57.26 tons and is forecasted to increase to about 111.8 tons by 2025. Bovine lactoferrin (bLf) concentration in milk is normally about 100 mg/L (with a range of 70–120 mg/L). Owing to the availability of many cows in this region, the supply of bovine lactoferrin will be more. In the 24 major states, the number of milk cows on farms was 8.94 million head 88,000 head more than in February 2020, and 2,000 head more than in January 2021. In the United States, the number of milk cows on farms was 9.46 million, 81,000 head more than in February 2020 and 3,000 head more than in January 2021. Hence, this region is estimated to dominate the market due to the presence of many cows.
Bovine Lactoferrin Companies and Competitive Landscape
Major key players present in the global bovine lactoferrin market are Fonterra Group, Bega Cheese, FrieslandCampina (DMV), Milei Gmbh, Glanbia Nutritionals, Westland Milk, Tatua, Synlait Milk, WBC, Murray Goulburn, and Ingredia Nutritional
Fonterra Group
Overview: Fonterra Cooperative Group is the world's largest dairy exporter, a leader in dairy research and innovation, the owner of a considerable portfolio of Asian Pacific brands, and a partner to many of the world's leading food companies. Fonterra has offices in more than 40 countries across the world with its headquarters in New Zealand.
Product Portfolio: The company comprises Dairy, Nutrition, and Dairy Ingredients.
Key Development: In 2020, Fonterra Australia signed an agreement to buy Dairy Country to help the company's premier Australian cheese division become more efficient.
